Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.42 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 4/20 | 0.96 |
| ▸ | NOS2 | P35228 | 4/20 | 0.96 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | NOS1 | P29475 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CHKA | P35790 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432593 | 0.98 | NOS3 (1.00) | NOS3NOS2DYRK1ANOS1KDM4E | |
| SCHEMBL59927 | 0.98 | NOS3 (1.00) | NOS3NOS2DYRK1ANOS1KDM4E | |
| Hydrochloric Acid SCHEMBL31372470 | 0.96 | NOS3 (0.96) | NOS3NOS2DYRK1ANOS1KDM4E | |
| SCHEMBL9629714 | 0.81 | NOS3 (0.69) | NOS3NOS2DYRK1AKDM4EBACE1 | |
| SCHEMBL16671291 | 0.81 | NOS3 (0.70) | NOS3NOS2DYRK1ANOS1KDM4E | |
| SCHEMBL14637261 | 0.81 | NOS3 (0.70) | NOS3NOS2DYRK1ANOS1KDM4E | |
| SCHEMBL16637988 | 0.81 | NOS3 (0.70) | NOS3NOS2DYRK1ANOS1KDM4E | |
| SCHEMBL2640650 | 0.78 | NOS3 (0.63) | NOS3NOS2KDM4EMAPT | |
| SCHEMBL22670291 | 0.76 | NOS3 (0.63) | NOS3NOS2DYRK1ANOS1KDM4E | |
| SCHEMBL16671313 | 0.76 | NOS3 (0.63) | NOS3NOS2DYRK1ANOS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | ADRB1 3953/4885ADRB2 4114/4885NOS3 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.